Retrospective Study of the Effects of Sub-pathologic Phenotypes of BP on Clinical Management and Prognosis

Last updated: January 10, 2024
Sponsor: Xijing Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Epidermolysis Bullosa

Pemphigus Vulgaris (Pv)

Treatment

This is a retrospective analysis of health data from inpatient record, no intervention was designed

Clinical Study ID

NCT06213909
XijingH-PF-KY20232420-C-1
  • Ages < 100
  • All Genders

Study Summary

Bullous pemphigoid (BP) is a chronic autoimmune subepidermal blistering disease primarily affecting the elderly with a significant risk of mortality and morbidity. Various inflammatory cells such as eosinophils, lymphocytes, neutrophils and their granulopoiesis play an important role in the pathogenesis of BP. Infiltration of peripheral blood eosinophils, lymphocytes, and neutrophils into the skin is considered a major feature of BP, making it a heterogeneous disease with different histologic and clinical subtypes. This clinical study was conducted to further investigate the impact of different pathologic phenotypes of BP on the treatment and prognosis of the disease. A retrospective epidemiologic investigative approach was used,and case collection included demographic information, medical history, clinical manifestations, and histopathologic features. Including gender, age, duration of disease, number of days of hospitalization, mucosal involvement, clinical diagnosis before admission, histopathological diagnosis, laboratory tests, concomitant diseases, treatment and its changes in laboratory indexes before and after treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • (1) Patients with Bullous Pemphigoid who were first hospitalized in the Department ofDermatology of Xijing Hospital
  • (2) Age 0-100 years old, gender is not limited.
  • (3) Diagnosis is confirmed by clinical, histopathologic, immunopathologic and/oranti-BP180 antibody tests.
  • (4) Complete skin histopathology information

Exclusion

Exclusion Criteria:

  • (1) Patients with Bullous Pemphigoid who were not first diagnosed in our hospital.
  • (2) Those who have received systemic glucocorticoid, immunosuppressant, biologic, orother drug therapy within the past month.

Study Design

Total Participants: 318
Treatment Group(s): 1
Primary Treatment: This is a retrospective analysis of health data from inpatient record, no intervention was designed
Phase:
Study Start date:
January 11, 2024
Estimated Completion Date:
June 30, 2024

Connect with a study center

  • Xijing Hospital

    Xi'an, Shaanxi 710032
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.